Research Progress of Anti-angiogenic Agents Combined with Immunotherapy
in Patients with Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.101.05
- Author:
Jingyi WANG
1
;
Wenying PENG
1
;
Meilin JIANG
1
;
Lin WU
1
Author Information
1. The Second Department of Thoracic Oncology, the Affiliated Cancer Hospital of Xiangya School of Medicine,
Central South University/Hunan Cancer Hospital, Changsha 410013, China.
- Publication Type:Journal Article
- Keywords:
Anti-angiogenic agents;
Immune checkpoint inhibitor;
Lung neoplasms;
Tumor immune microenvironment
- From:
Chinese Journal of Lung Cancer
2021;24(3):196-203
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer has the highest incidence rate and mortality in China, even in the world, and non-small cell lung cancer (NSCLC) accounts for about 85%. The growth and metastasis of tumor depend on the generation of blood vessels, and anti-angiogenic therapy is playing an increasingly important role, however, no significant improvement was observed in the underwent anti-angiogenic agents used for patients alone. In recent years, the application of immune checkpoint inhibitor (ICI) has significantly improved the prognosis of some lung cancer patients, however, the objective response rate of patients receiving ICI alone is low. While anti-angiogenic agents and ICI both regulate the tumor immune microenvironment and have a potential synergistic mechanism, showing a bright prospect in the combined application of anti-tumor therapy. In this review, we focused on the research and application of anti-angiogenic agents in combination with ICI in advanced non-small cell lung cancer.
